View the website in Vertical mode on Mobile

Exel Way Pharma

Investing in a European medical start-up.

Exel Way Pharma is a Portuguese based cannabis company focused on industrial cultivation and production of medical grade cannabis (MGC) products and derivatives (i.e. cannabinoids, terpenes, etc.) in a wide range of levels and values.

Principal markets include the European Union and other continental European countries such as Switzerland, the United Kingdom, and Norway.

Opportunity

  • European market – forecasted addressable market of 10.2 million patients with a total market potential of USD 30+ billion by 2028.
  • Overall European market expected to have a compounded annual growth rate (CAGR) of 67.4% from 2022 onward.
  • Proprietary seed technology from Israel.
  • Clearly defined exit strategy.

Transformative investment designed to create a player ripe for acquisition by a strategic.

Project Team

Steven M. Pepa, Director → bio

Dr. Oded Sagee, Chief Science Officer → bio

 

See all Case Studies articles

No items found.
Related articles

Why are Americans looking to buy a home in Portugal?

Over the last couple of years, real estate agencies all over Portugal have noticed a new client demand from overseas...
Learn more

Portugal: A safe real estate investment

Foreign buyers snap up Portugal's most expensive properties, demonstrating future investment opportunity.
Learn more

Americans become interested in Portugal’s Golden Visa Program; fund options set to rise

This last November, Americans became the main driver for Golden Visa, with approvals rising from 6 in the spring to...
Learn more
Saratoga Capital Partners is a private equity and alternative asset management group. The partnership was founded in 2008, and was initially purposed as a mergers and acquisitions advisory and capital raising boutique. We focus on special situations, unlocking deep value from substantially underpriced assets or opportunities. We seek to maximize investor value and return whilst at the same time providing opportunity for our portfolio companies and their respective stakeholders.
Investment Programs Cyprus Residency Program Greece Citizenship Program Portugal Golden Visa Program Turkey Citizenship Program
Investor Relations Corporate Governance Regulatory Information Updates
About Us Client Login Contact Us
© 2022 Saratoga Capital Partners
Legal
Data Protection and Privacy
© 2022 Saratoga Capital Partners
Legal
Data Protection and Privacy